Blurbs

J.P. Morgan Thinks IDEAYA Biosciences’ Stock is Going to Recover

In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on IDEAYA Biosciences (IDYAResearch Report), with a price target of $30.00. The company’s shares closed last Thursday at $10.12, close to its 52-week low of $8.14.

According to TipRanks.com, Rama has 0 stars on 0-5 stars ranking scale with an average return of -7.2% and a 37.2% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Protagonist Therapeutics, and Springworks Therapeutics.

IDEAYA Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $22.00, representing a 138.1% upside. In a report issued on May 11, Stifel Nicolaus also maintained a Buy rating on the stock with a $16.00 price target.

See the top stocks recommended by analysts >>

IDEAYA Biosciences’ market cap is currently $390.9M and has a P/E ratio of -6.86.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Read More on IDYA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More